Contact

Our portfolio

DCPrime

Pioneering cancer vaccines, DCPrime leverages its DCOne® dendritic cell technology to develop innovative immunotherapies. Their lead candidate, DCP-001, is currently in a Phase 2 study for Acute Myeloid Leukemia (AML), building on promising Phase 1 results. With Orphan Medicinal Product designation in the EU, DCPrime aims to provide effective treatments for hematological cancers, including Multiple Myeloma, and is expanding its platform to target solid tumors and explore synergies with immune modulators.

  • Institute: Amsterdam UMC
Industry: Biotechnology, Immunology, Oncology
  • Founding year: 2005
Visit website

Want to get in contact about DCPrime?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Haermonics
Preventing post-surgical complications with the PURE pericardial flushing device.
InspectT
Enabling standard spectrometers to simultaneously measure both chemical composition and particle size by integrating patented, cost-effective Optical-DOSY flow cells.
Eddytec
Providing advanced defect detection for carbon composites in aerospace and wind energy.
Inreda Diabetic
Improving diabetes management with the AP, a closed-loop bi-hormonal artificial pancreas.
Haermonics
Preventing post-surgical complications with the PURE pericardial flushing device.
InspectT
Enabling standard spectrometers to simultaneously measure both chemical composition and particle size by integrating patented, cost-effective Optical-DOSY flow cells.
Eddytec
Providing advanced defect detection for carbon composites in aerospace and wind energy.
Inreda Diabetic
Improving diabetes management with the AP, a closed-loop bi-hormonal artificial pancreas.
Explore full AAV portfolio
Contact